Veeva Systems (VEEV)
(Delayed Data from NYSE)
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Veeva Systems (VEEV) Vault Quality Suite Gets Adopted by CBM
by Zacks Equity Research
Veeva Systems' (VEEV) product gets adopted by CBM. This can drive the development and delivery of groundbreaking treatments for patients.
Veeva Systems (VEEV) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $315.54, moving -0.67% from the previous trading session.
Veeva Systems (VEEV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $320.45 in the latest trading session, marking a +0.51% move from the prior day.
Veeva Systems (VEEV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $314.81, marking a -0.69% move from the previous day.
Veeva Systems (VEEV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $322.99, marking a +0.42% move from the previous day.
Syneos Health's (SYNH) New Pact Boosts Tech-Driven Solutions
by Zacks Equity Research
Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.
Veeva Systems' (VEEV) eConsent Solution Gets Adopted by Celerion
by Zacks Equity Research
Veeva Systems' (VEEV) solution gets adopted by Celerion in a bid to boost paperless clinical trials.
Veeva Systems' (VEEV) Deal to Enhance Digital Clinical Trials
by Zacks Equity Research
Veeva Systems' (VEEV) partnership with Leo Pharma to significantly boost the clinical trial process for patients, sites and sponsors.
Veeva (VEEV) Down 8.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of product launches and robust product adoptions.
Veeva Systems' (VEEV) New Offering to Optimize Lab Operations
by Zacks Equity Research
Veeva Systems' (VEEV) Vault LIMS is expected to help manufacturers optimize lab management and significantly simplify their systems landscape via a unified suite of quality and lab applications.
Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes
by Zacks Equity Research
Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
by Debanjana Dey
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
Veeva Systems (VEEV) Q2 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both its segments.
Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 9.30% and 0.96%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials
by Zacks Equity Research
Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Veeva Systems (VEEV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Veeva (VEEV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veeva Systems (VEEV) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal second-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Veeva Systems (VEEV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $322.44, marking a +0.54% move from the previous day.
Veeva Systems (VEEV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $319.22, marking a -0.8% move from the previous day.
Veeva Systems (VEEV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $332.34 in the latest trading session, marking a -1.91% move from the prior day.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $332.78 in the latest trading session, marking a +0.02% move from the prior day.
Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning
by Zacks Equity Research
Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.
PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.